What is the underlying mechanism of the 6 H’s syndrome (elevated fibroblast growth factor‑23, hypophosphatemia, hyperphosphaturia, hypocalcemia, secondary hyperparathyroidism) that occurs after administration of Ferinject (ferric carboxymaltose)?

Mechanism of 6H Syndrome After Ferric Carboxymaltose

Ferric carboxymaltose (FCM) triggers a sharp surge in intact fibroblast growth factor 23 (iFGF23) from osteocytes, which initiates a pathophysiological cascade of renal phosphate wasting that persists even after FGF23 levels normalize, creating the constellation of metabolic derangements known as the 6H syndrome 1.

The Pathophysiological Cascade

The mechanism unfolds in a specific sequence:

Primary Event: FGF23 Surge

FCM administration causes osteocytes to release massive amounts of intact FGF23 into circulation 2, 3. This elevation can increase iFGF23 by over 134% within the first two weeks 2. Importantly, while iFGF23 rises dramatically, c-terminal FGF23 (cFGF23) actually decreases by over 500%, indicating that the intact, biologically active form is specifically elevated 2.

Secondary Effects: The Renal Cascade

The elevated iFGF23 acts on the kidneys through FGF receptors (FGFR1-4) with Klotho as a co-receptor, triggering three critical renal effects 4:

1. Hyperphosphaturia: FGF23 directly increases renal phosphate excretion by downregulating sodium-phosphate cotransporters in the proximal tubule. Fractional excretion of phosphate (FePi) increases significantly, with urinary phosphate losses exceeding 109 mmol/day in severe cases 5, 2.

2. Hypocalcitriolemia: FGF23 suppresses 1-alpha-hydroxylase (the enzyme that produces active vitamin D) and upregulates 24-hydroxylase (which degrades calcitriol). This creates a profound deficiency of 1,25-dihydroxyvitamin D 2, 4.

3. Hypocalcemia: The combination of reduced calcitriol (which normally enhances intestinal calcium absorption) and ongoing phosphate wasting leads to decreased serum calcium 2.

Tertiary Response: Secondary Hyperparathyroidism

The hypocalcemia and hypophosphatemia trigger compensatory parathyroid hormone (PTH) elevation 2, 4. However, this PTH response is paradoxically ineffective because:

• The elevated FGF23 continues to drive renal phosphate wasting despite PTH's attempt to retain phosphate
• The suppressed calcitriol prevents PTH from effectively mobilizing calcium from bone
• Administering phosphate supplementation actually worsens the situation by further raising PTH and exacerbating phosphaturia 1

The Critical Timing Issue

The hypophosphatemia persists long after FGF23 levels return to normal 1. This temporal disconnect occurs because:

• The renal tubular dysfunction induced by the FGF23 surge takes weeks to resolve
• The secondary hyperparathyroidism becomes self-perpetuating
• Bone mineralization defects (evidenced by elevated bone-specific alkaline phosphatase) develop and require time to heal 2

Why FCM Specifically?

Not all IV iron formulations cause this syndrome. FCM's unique carbohydrate shell structure appears to directly stimulate osteocyte FGF23 production in a way that other formulations do not 3, 6. Clinical trials demonstrate FCM-associated hypophosphatemia rates of 50-92% versus only 2-8% with other IV iron preparations 7.

Clinical Implications of the Mechanism

Understanding this cascade explains several clinical observations:

• Normal renal function is a risk factor (not protective) because intact kidneys respond fully to FGF23's phosphaturic effects 1, 6
• Oral phosphate supplementation fails because it cannot overcome the ongoing renal losses and may worsen secondary hyperparathyroidism 1
• Repeat dosing is particularly dangerous because it re-triggers the FGF23 surge before recovery from the first episode, leading to osteomalacia and fractures 1, 7
• Malabsorptive disorders (like celiac disease) compound the problem by preventing effective oral repletion of both phosphate and vitamin D 5

The "6H" Framework

The syndrome encompasses:

1. High FGF23 (the primary driver)
2. Hyperphosphaturia (renal phosphate wasting)
3. Hypophosphatemia (the clinical hallmark)
4. Hypocalcitriolemia (suppressed active vitamin D)
5. Hypocalcemia (from reduced calcitriol)
6. Hyperparathyroidism (secondary compensatory response)

This framework is diagnostically useful because finding this constellation of abnormalities immediately points to FCM-induced FGF23-mediated phosphate wasting rather than other causes of hypophosphatemia 5.

Key Mechanistic Pitfall

The most critical error is attempting phosphate repletion without addressing the underlying FGF23-driven phosphaturia. The only effective management is cessation of FCM and time for the renal tubular dysfunction to resolve 1. Treatment should focus on mitigating secondary hyperparathyroidism with vitamin D supplementation (not phosphate), and in severe cases, continuous IV phosphate may be required for 5-8 weeks until the kidneys recover their ability to retain phosphate 5.